Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cell (MSC) therapies have been used in clinical trials in various fields. These cells are easily expanded, show low immunogenicity, can be acquired from medical waste, and have multiple functions, suggesting their potential applications in a variety of diseases, including liver disease and inflammatory bowel disease. MSCs help prepare the microenvironment, in response to inflammatory cytokines, by producing immunoregulatory factors that modulate the progression of inflammation by affecting dendritic cells, B cells, T cells, and macrophages. MSCs also produce a large amount of cytokines, chemokines, and growth factors, including exosomes that stimulate angiogenesis, prevent apoptosis, block oxidation reactions, promote remodeling of the extracellular matrix, and induce differentiation of tissue stem cells. According to ClinicalTrials.gov, more than 680 clinical trials using MSCs are registered for cell therapy of many fields including liver diseases (more than 40 trials) and inflammatory bowel diseases (more than 20 trials). In this report, we introduce background and clinical studies of MSCs in liver disease and inflammatory bowel diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622 · cited 1×
“[32] reported a phase I study of refractory luminal CD using autologous bone marrow-derived MSCs and confirmed the safety and feasibility of MSC therapy.”
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 1×
“[14] reported phase I–II clinical trials using autologous bone marrow-derived MSCs against liver cirrhosis with a variety of etiologies, and improvement of liver function was confirmed.”
Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372
Thomas, J. A., Pope, C., Wojtacha, D., Robson, A. J., Gordon-Walker, T. T., Hartland, S., Ramachandran, P., Van Deemter, M., Hume, D. A., Iredale, J. P., et al. (2011) · Hepatology · doi:10.1002/hep.24315 · Cited by 346
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
Saito, T., Okumoto, K., Haga, H., Nishise, Y., Ishii, R., Sato, C., Watanabe, H., Okada, A., Ikeda, M., Togashi, H., et al. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0074 · Cited by 75
Self-citation
Cited by
Watanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Self-citationKojima, Y., Tsuchiya, A., Ogawa, M., Nojiri, S., Takeuchi, S., Watanabe, T., Nakajima, K., Hara, Y., Yamashita, J., Kikuta, J., et al. (2019) · Regenerative Therapy · doi:10.1016/j.reth.2019.08.005 · Cited by 43
“The cells were administered by injection into the peripheral vein, hepatic artery, or portal vein [9].”
BackgroundSelf-citationHamilton, A. M., Foster, P. J., & Ronald, J. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.111 · Cited by 17
Iwasawa, T., Nojiri, S., Tsuchiya, A., Takeuchi, S., Watanabe, T., Ogawa, M., Motegi, S., Sato, T., Kumagai, M., Nakaya, T., et al. (2021) · Regenerative Therapy · doi:10.1016/j.reth.2021.07.002 · Cited by 14
Self-citation
Metadata
- Authors
- Tsuchiya, A., Kojima, Y., Ikarashi, S., Seino, S., Watanabe, Y., Kawata, Y., & Terai, S.
- Venue
- Inflammation and Regeneration
- Published
- 2017-07-03
- Volume
- 37
- Issue
- 1
- Pages
- 16-16
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- OpenAlex
- W2727272993
- Cited by
- 81
- References
- 8
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. https://app.cochat.ai/papers/10.1186/s41232-017-0045-6
- The paper
- Tsuchiya, A., Kojima, Y., Ikarashi, S., Seino, S., Watanabe, Y., Kawata, Y., & Terai, S. (2017). Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflammation and Regeneration. https://doi.org/10.1186/s41232-017-0045-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.